Study of OTS-412 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new virus-based therapy (OTS-412) that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments, including immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You must have a solid tumor that has not responded well to standard treatments like immunotherapy or targeted therapy.
- You need at least one tumor that can be safely injected with a needle, either under the skin or with ultrasound guidance.
- Your tumor(s) should be about the size of a pea or larger (depending on the dose group).
- You must have good enough health to undergo the study, including adequate kidney, liver, and blood cell counts.
- You cannot have a history of autoimmune disease, organ transplant, or recent use of blood thinners or antiviral drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a cancer-killing virus (OTS-412) that is injected directly into tumors. It is for people with solid tumors that have not responded to standard treatments, including immunotherapy. The goal is to see if the virus can shrink or control the injected tumors.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This trial tests a new drug called SOT201 for people with advanced solid cancers that have stopped responding to other treatments. It helps the immune system fight the cancer more effectively.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
Hear when a new Treatment-Refractory Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.